(Q37659101)

English

Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium

scientific article published on 21 September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 August 2017

Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium (English)

1 reference

Europe PubMed Central

21 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

Stephen P Hunger

7

object named as

Stephen P Hunger

1 reference

Europe PubMed Central

21 August 2017

author name string

Tanya M Trippett

1

1 reference

Europe PubMed Central

21 August 2017

Cynthia Herzog

2

1 reference

Europe PubMed Central

21 August 2017

James A Whitlock

3

1 reference

Europe PubMed Central

21 August 2017

Johannes Wolff

4

1 reference

Europe PubMed Central

21 August 2017

John Kuttesch

5

1 reference

Europe PubMed Central

21 August 2017

Rochelle Bagatell

6

1 reference

Europe PubMed Central

21 August 2017

Jessica Boklan

8

1 reference

Europe PubMed Central

21 August 2017

Amy A Smith

9

1 reference

Europe PubMed Central

21 August 2017

Robert J Arceci

10

1 reference

Europe PubMed Central

21 August 2017

Howard M Katzenstein

11

1 reference

Europe PubMed Central

21 August 2017

Christopher Harbison

12

1 reference

Europe PubMed Central

21 August 2017

Xiaofei Zhou

13

1 reference

Europe PubMed Central

21 August 2017

Haolan Lu

14

1 reference

Europe PubMed Central

21 August 2017

Christiane Langer

15

1 reference

Europe PubMed Central

21 August 2017

Martin Weber

16

1 reference

Europe PubMed Central

21 August 2017

Lia Gore

17

1 reference

Europe PubMed Central

21 August 2017

language of work or name

0 references

publication date

21 September 2009

1 reference

Europe PubMed Central

21 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

21 August 2017

27

1 reference

Europe PubMed Central

21 August 2017

30

1 reference

Europe PubMed Central

21 August 2017

5102-5108

1 reference

Europe PubMed Central

21 August 2017

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Cetuximab for the treatment of colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Pediatric cancers in the new millennium: dramatic progress, new challenges.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Antibody pharmacokinetics and pharmacodynamics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

23 August 2017

Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

6 September 2017

Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

6 September 2017

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

14 September 2017

Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

14 September 2017

Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms’ tumor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

14 September 2017

Epidermal growth factor receptor gene amplification and expression in disseminated pediatric low-grade gliomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

1 September 2018

Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

1 September 2018

Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

1 September 2018

Recommendations of the Brain Tumor Subcommittee for the reporting of trials. SIOP Brain Tumor Subcommittee. International Society of Pediatric Oncology.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

1 September 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

1 September 2018

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5321093

3 December 2018

Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19770383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan for children with relapsed solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19770383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19770383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

1 reference

https://pubmed.ncbi.nlm.nih.gov/19770383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/19770383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/19770383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19770383

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.20.8975

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37659101&oldid=2143281129"